Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dry Powder Inhaler

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    96 result(s) found for: Dry Powder Inhaler. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-004979-35 Sponsor Protocol Number: 05-FOR-01 SE Start Date*: 2006-11-27
    Sponsor Name:Andi - Ventis
    Full Title: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS BRONCHODILATION, SAFETY AND TOLERABILITY OF NEW GENERIC DRY POWDER FORMOTEROL FORMULATIONS GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALE...
    Medical condition: reversible mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-004437-16 Sponsor Protocol Number: tobra-02 Start Date*: 2013-05-15
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis
    Medical condition: Bronchiectasis Lung infections
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003826-24 Sponsor Protocol Number: 05-FOR-01 Start Date*: 2005-10-18
    Sponsor Name:Andi - Ventis
    Full Title: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALER AND TWO...
    Medical condition: reversible mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003872-20 Sponsor Protocol Number: 07-LICFOR-01 Start Date*: 2007-11-08
    Sponsor Name:Laboratorios Liconsa S.A.
    Full Title: A RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN FROM A NOVEL DRY POWDER INHALER CO...
    Medical condition: This study has been initianed to assess the bronchodilating properties of a new generic dry powder formoterol formulation given from a novel dry powder inhaler compared to the reference Foradil Aer...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000735-14 Sponsor Protocol Number: L-A/2017/COM/01 Start Date*: 2018-01-19
    Sponsor Name:Lek-Am Sp. z o.o.
    Full Title: The efficacy and safety of new formulation of combination of fluticasone propionate / salmeterol (125μg / 25μg) in MDI HFA inhaler compared with the reference drug at a dose of 500μg / 50μg in DPI...
    Medical condition: Asthma is a common, chronic respiratory disease affecting 1–18% of the population in different countries. Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightnes...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-005014-21 Sponsor Protocol Number: DPI-tobra-kind Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis
    Medical condition: Cystic Fibrosis Lung infections
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005030-19 Sponsor Protocol Number: VR506/2/004 Start Date*: 2012-08-17
    Sponsor Name:Vectura Limited
    Full Title: A randomised double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily doses of fluticasone propionate inhaled from a new dry powder inhale...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) PL (Completed) BG (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001740-24 Sponsor Protocol Number: BY9010/M1-302 Start Date*: Information not available in EudraCT
    Sponsor Name:ALTANA Pharma AG
    Full Title: A Dose Range Finding Study of Formoterol Fumarate administered twice daily using the Ultrahaler™ in Patients with Asthma
    Medical condition: asthma bronchial
    Disease: Version SOC Term Classification Code Term Level
    8.0 10003555 llt
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001772-19 Sponsor Protocol Number: VR506/2/002 Start Date*: 2011-11-29
    Sponsor Name:Vectura Limited
    Full Title: A randomised, double-blind, placebo controlled, parallel group, study to evaluate the efficacy and safety of VR506 inhalation powder from a new dry powder inhaler in adolescent and adult subjects w...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002930-21 Sponsor Protocol Number: P03418 Start Date*: 2006-11-01
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Den...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005047-40 Sponsor Protocol Number: SIT001-12 Start Date*: 2015-03-25
    Sponsor Name:Sanofi-Aventis AG
    Full Title: A Randomized, Double Blind, Single Dose, Crossover Study, in Subjects with Mild to Moderate Asthma, to Compare the Pharmacodynamic (Bronchodilator) Responses of 12.5/250 µg and 50/250 µg Salmeterol...
    Medical condition: Mild to moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10003565 Asthmatic LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002157-23 Sponsor Protocol Number: 2007-FOR-EL-02 Start Date*: 2008-05-13
    Sponsor Name:Elpen Pharmaceutical Co. Inc.
    Full Title: A 8-week, multicentre, randomized, double-blind, double-dummy, parallel group, non-inferiority study, comparing Formoterol (Formopen®) administered via Elpenhaler® Dry Powder Inhaler versus the inn...
    Medical condition: Patients with mild to moderate persistent asthma, as defined by GINA criteria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003655-36 Sponsor Protocol Number: CQVA149A2204 Start Date*: 2008-02-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000753-31 Sponsor Protocol Number: HZA102942 Start Date*: 2012-03-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to invstigate the safety, tolerability,pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoa...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000741-12 Sponsor Protocol Number: HZA112776 Start Date*: 2012-03-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double blind, Placebo controlled, Two-Way Crossover 7-day study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25μg in ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000923-25 Sponsor Protocol Number: FSS-AS-30017 Start Date*: 2014-11-07
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler i...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003774-27 Sponsor Protocol Number: BC-180-12 Start Date*: 2014-01-20
    Sponsor Name:AlgiPharma AS
    Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati...
    Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004708-19 Sponsor Protocol Number: BY9010/M1-506 Start Date*: 2005-04-21
    Sponsor Name:ALTANA Pharma AG
    Full Title: A dose range finding study of formoterol administered once daily in the evening in combination with ciclesonide using the UltrahalerTM versus monotherapy of each drug in asthmatic patients
    Medical condition: asthma bronchiale
    Disease: Version SOC Term Classification Code Term Level
    5.1 10003553 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-000582-36 Sponsor Protocol Number: BTA51-350-201 Start Date*: 2013-11-04
    Sponsor Name:Biota Scientific Management Pty Ltd.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults with Sympto...
    Medical condition: Treatment of influenza caused by viruses type A and B
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) LV (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001149-25 Sponsor Protocol Number: FSS-AS-301 Start Date*: 2014-11-07
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler i...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA